Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

Nancy L Monson, Petra D. Cravens, Elliot Frohman, Kathleen Hawker, Michael K. Racke

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown. Objective: To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis. Design: Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment. Results: The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment. Conclusion: The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalArchives of Neurology
Volume62
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Chronic Progressive Multiple Sclerosis
Cerebrospinal Fluid
B-Lymphocytes
B-Lymphocyte Subsets
Rituximab
Cells
Blood
Multiple Sclerosis
Central Nervous System Diseases
Blood Cells
Flow Cytometry
Therapeutics
Monoclonal Antibodies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. / Monson, Nancy L; Cravens, Petra D.; Frohman, Elliot; Hawker, Kathleen; Racke, Michael K.

In: Archives of Neurology, Vol. 62, No. 2, 02.2005, p. 258-264.

Research output: Contribution to journalArticle

@article{f349f0282e10474eb47e2f03d8dca08f,
title = "Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis",
abstract = "Background: Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown. Objective: To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis. Design: Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment. Results: The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment. Conclusion: The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.",
author = "Monson, {Nancy L} and Cravens, {Petra D.} and Elliot Frohman and Kathleen Hawker and Racke, {Michael K.}",
year = "2005",
month = "2",
doi = "10.1001/archneur.62.2.258",
language = "English (US)",
volume = "62",
pages = "258--264",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

AU - Monson, Nancy L

AU - Cravens, Petra D.

AU - Frohman, Elliot

AU - Hawker, Kathleen

AU - Racke, Michael K.

PY - 2005/2

Y1 - 2005/2

N2 - Background: Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown. Objective: To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis. Design: Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment. Results: The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment. Conclusion: The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.

AB - Background: Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown. Objective: To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis. Design: Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment. Results: The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment. Conclusion: The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.

UR - http://www.scopus.com/inward/record.url?scp=13444274684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444274684&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.2.258

DO - 10.1001/archneur.62.2.258

M3 - Article

C2 - 15710854

AN - SCOPUS:13444274684

VL - 62

SP - 258

EP - 264

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 2

ER -